Investors

2023

OptiBiotix Health Plc (AIM: OPTI), a Life Sciences business developing compounds to tackle obesity, high cholesterol and diabetes, announces its results for the six months ended 31 May 2015.

OptiBiotix continues to make progress on its strategy of developing compounds which modify the human microbiome and commercialising these through partnering with food, health, and wellbeing companies.

Highlights

• The appointment of Jim Laird as Commercial Director to the Board to increase commercial capacity and capability
• The completion of preclinical studies and ethics approval received to enable human clinical studies to begin for the Company's cholesterol lowering product
• Expansion of the OptiBiotic® platform to a wider range of microbial species broadening the number of product and partner opportunities
• The filing of four new patents
• Creating a joint venture with Nizo Food Research to develop, manufacture and distribute weight management yoghurts to global markets

Post-period end highlights

• Announcement of an option agreement with a multinational consumer goods company for the cholesterol lowering product
• Strategic alliance with Venture Life
• Agreement with Spanish National Research Council

Stephen O'Hara, CEO of OptiBiotix commented: "I am delighted with the progress OptiBiotix has made since joining AIM in August 2014. In a short space of time we have moved one of our development programmes into clinical studies, progressed our sugar programme designed to create low calorie, sweet oligosaccharides to reduce chronic lifestyle disease such as heart disease, obesity and diabetes, built on our IP portfolio, and reached agreements with a number of commercial partners. During the period, we strengthened the Board with the appointment of Jim Laird, who has brought industry specific commercial and corporate expertise to the Company. I would like to thank our investors for their support since we joined AIM, and look forward to an exciting and rewarding rest of 2015."

For further information, please contact:

About OptiBiotix Health Plc - www.optibiotix.com

OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease. The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.

OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.

2022

OptiBiotix Health Plc (AIM: OPTI), a Life Sciences business developing compounds to tackle obesity, high cholesterol and diabetes, announces its results for the six months ended 31 May 2015.

OptiBiotix continues to make progress on its strategy of developing compounds which modify the human microbiome and commercialising these through partnering with food, health, and wellbeing companies.

Highlights

• The appointment of Jim Laird as Commercial Director to the Board to increase commercial capacity and capability
• The completion of preclinical studies and ethics approval received to enable human clinical studies to begin for the Company's cholesterol lowering product
• Expansion of the OptiBiotic® platform to a wider range of microbial species broadening the number of product and partner opportunities
• The filing of four new patents
• Creating a joint venture with Nizo Food Research to develop, manufacture and distribute weight management yoghurts to global markets

Post-period end highlights

• Announcement of an option agreement with a multinational consumer goods company for the cholesterol lowering product
• Strategic alliance with Venture Life
• Agreement with Spanish National Research Council

Stephen O'Hara, CEO of OptiBiotix commented: "I am delighted with the progress OptiBiotix has made since joining AIM in August 2014. In a short space of time we have moved one of our development programmes into clinical studies, progressed our sugar programme designed to create low calorie, sweet oligosaccharides to reduce chronic lifestyle disease such as heart disease, obesity and diabetes, built on our IP portfolio, and reached agreements with a number of commercial partners. During the period, we strengthened the Board with the appointment of Jim Laird, who has brought industry specific commercial and corporate expertise to the Company. I would like to thank our investors for their support since we joined AIM, and look forward to an exciting and rewarding rest of 2015."

For further information, please contact:

About OptiBiotix Health Plc - www.optibiotix.com

OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease. The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.

OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.

2021

OptiBiotix Health Plc (AIM: OPTI), a Life Sciences business developing compounds to tackle obesity, high cholesterol and diabetes, announces its results for the six months ended 31 May 2015.

OptiBiotix continues to make progress on its strategy of developing compounds which modify the human microbiome and commercialising these through partnering with food, health, and wellbeing companies.

Highlights

• The appointment of Jim Laird as Commercial Director to the Board to increase commercial capacity and capability
• The completion of preclinical studies and ethics approval received to enable human clinical studies to begin for the Company's cholesterol lowering product
• Expansion of the OptiBiotic® platform to a wider range of microbial species broadening the number of product and partner opportunities
• The filing of four new patents
• Creating a joint venture with Nizo Food Research to develop, manufacture and distribute weight management yoghurts to global markets

Post-period end highlights

• Announcement of an option agreement with a multinational consumer goods company for the cholesterol lowering product
• Strategic alliance with Venture Life
• Agreement with Spanish National Research Council

Stephen O'Hara, CEO of OptiBiotix commented: "I am delighted with the progress OptiBiotix has made since joining AIM in August 2014. In a short space of time we have moved one of our development programmes into clinical studies, progressed our sugar programme designed to create low calorie, sweet oligosaccharides to reduce chronic lifestyle disease such as heart disease, obesity and diabetes, built on our IP portfolio, and reached agreements with a number of commercial partners. During the period, we strengthened the Board with the appointment of Jim Laird, who has brought industry specific commercial and corporate expertise to the Company. I would like to thank our investors for their support since we joined AIM, and look forward to an exciting and rewarding rest of 2015."

For further information, please contact:

About OptiBiotix Health Plc - www.optibiotix.com

OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease. The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.

OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.

2020

OptiBiotix Health Plc (AIM: OPTI), a Life Sciences business developing compounds to tackle obesity, high cholesterol and diabetes, announces its results for the six months ended 31 May 2015.

OptiBiotix continues to make progress on its strategy of developing compounds which modify the human microbiome and commercialising these through partnering with food, health, and wellbeing companies.

Highlights

• The appointment of Jim Laird as Commercial Director to the Board to increase commercial capacity and capability
• The completion of preclinical studies and ethics approval received to enable human clinical studies to begin for the Company's cholesterol lowering product
• Expansion of the OptiBiotic® platform to a wider range of microbial species broadening the number of product and partner opportunities
• The filing of four new patents
• Creating a joint venture with Nizo Food Research to develop, manufacture and distribute weight management yoghurts to global markets

Post-period end highlights

• Announcement of an option agreement with a multinational consumer goods company for the cholesterol lowering product
• Strategic alliance with Venture Life
• Agreement with Spanish National Research Council

Stephen O'Hara, CEO of OptiBiotix commented: "I am delighted with the progress OptiBiotix has made since joining AIM in August 2014. In a short space of time we have moved one of our development programmes into clinical studies, progressed our sugar programme designed to create low calorie, sweet oligosaccharides to reduce chronic lifestyle disease such as heart disease, obesity and diabetes, built on our IP portfolio, and reached agreements with a number of commercial partners. During the period, we strengthened the Board with the appointment of Jim Laird, who has brought industry specific commercial and corporate expertise to the Company. I would like to thank our investors for their support since we joined AIM, and look forward to an exciting and rewarding rest of 2015."

For further information, please contact:

About OptiBiotix Health Plc - www.optibiotix.com

OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease. The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.

OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.

2019

OptiBiotix Health Plc (AIM: OPTI), a Life Sciences business developing compounds to tackle obesity, high cholesterol and diabetes, announces its results for the six months ended 31 May 2015.

OptiBiotix continues to make progress on its strategy of developing compounds which modify the human microbiome and commercialising these through partnering with food, health, and wellbeing companies.

Highlights

• The appointment of Jim Laird as Commercial Director to the Board to increase commercial capacity and capability
• The completion of preclinical studies and ethics approval received to enable human clinical studies to begin for the Company's cholesterol lowering product
• Expansion of the OptiBiotic® platform to a wider range of microbial species broadening the number of product and partner opportunities
• The filing of four new patents
• Creating a joint venture with Nizo Food Research to develop, manufacture and distribute weight management yoghurts to global markets

Post-period end highlights

• Announcement of an option agreement with a multinational consumer goods company for the cholesterol lowering product
• Strategic alliance with Venture Life
• Agreement with Spanish National Research Council

Stephen O'Hara, CEO of OptiBiotix commented: "I am delighted with the progress OptiBiotix has made since joining AIM in August 2014. In a short space of time we have moved one of our development programmes into clinical studies, progressed our sugar programme designed to create low calorie, sweet oligosaccharides to reduce chronic lifestyle disease such as heart disease, obesity and diabetes, built on our IP portfolio, and reached agreements with a number of commercial partners. During the period, we strengthened the Board with the appointment of Jim Laird, who has brought industry specific commercial and corporate expertise to the Company. I would like to thank our investors for their support since we joined AIM, and look forward to an exciting and rewarding rest of 2015."

For further information, please contact:

About OptiBiotix Health Plc - www.optibiotix.com

OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease. The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.

OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.

2018

OptiBiotix Health Plc (AIM: OPTI), a Life Sciences business developing compounds to tackle obesity, high cholesterol and diabetes, announces its results for the six months ended 31 May 2015.

OptiBiotix continues to make progress on its strategy of developing compounds which modify the human microbiome and commercialising these through partnering with food, health, and wellbeing companies.

Highlights

• The appointment of Jim Laird as Commercial Director to the Board to increase commercial capacity and capability
• The completion of preclinical studies and ethics approval received to enable human clinical studies to begin for the Company's cholesterol lowering product
• Expansion of the OptiBiotic® platform to a wider range of microbial species broadening the number of product and partner opportunities
• The filing of four new patents
• Creating a joint venture with Nizo Food Research to develop, manufacture and distribute weight management yoghurts to global markets

Post-period end highlights

• Announcement of an option agreement with a multinational consumer goods company for the cholesterol lowering product
• Strategic alliance with Venture Life
• Agreement with Spanish National Research Council

Stephen O'Hara, CEO of OptiBiotix commented: "I am delighted with the progress OptiBiotix has made since joining AIM in August 2014. In a short space of time we have moved one of our development programmes into clinical studies, progressed our sugar programme designed to create low calorie, sweet oligosaccharides to reduce chronic lifestyle disease such as heart disease, obesity and diabetes, built on our IP portfolio, and reached agreements with a number of commercial partners. During the period, we strengthened the Board with the appointment of Jim Laird, who has brought industry specific commercial and corporate expertise to the Company. I would like to thank our investors for their support since we joined AIM, and look forward to an exciting and rewarding rest of 2015."

For further information, please contact:

About OptiBiotix Health Plc - www.optibiotix.com

OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease. The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.

OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.